Loading
A phase 1/2 trial of Cemiplimab in metastatic cancer and melanoma, run by OncoResponse, Inc., now recruiting.
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents is a phase 1/2 interventional study registered as NCT06090266 by OncoResponse, Inc., with 168 participants planned, started 2023-10-24 and due to reach its primary completion in 2026-08-01. Interventions recorded: OR502, Cemiplimab. Conditions listed: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer. No results are recorded here; the registry entry is the source.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Metastatic cancer (cancer that has spread).
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Melanoma.